series-b
Stage
1
Investors
About
Egetis Therapeutics is a pharmaceutical company developing treatments for rare diseases, including Emcitate (tiratricol) for MCT8 deficiency, which has EMA approval, and Aladote (calmangafodipir) for acetaminophen overdose.
Explore Egetis Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.